Bio-Rad Laboratories (Bio-Rad Laboratories) EBIT

: $-801 Mil (TTM As of Dec. 2023)

View and export this data going back to 1980. Start your Free Trial

Bio-Rad Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $441 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-801 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bio-Rad Laboratories's annualized ROC % for the quarter that ended in Dec. 2023 was 3.09%. Bio-Rad Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 108.04%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bio-Rad Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -10.28%.

Bio-Rad Laboratories EBIT Historical Data

The historical data trend for Bio-Rad Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

2,284.50

4,939.87

5,450.61

-4,666.16

-800.67

Bio-Rad Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															1,102.97	97.17	-1,488.08	149.50	440.75

Competitive Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories EV-to-EBIT Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's EV-to-EBIT falls into.

Bio-Rad Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-801 Mil.

Bio-Rad Laboratories (NYSE:BIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bio-Rad Laboratories's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	381.268 * ( 1 - 18.37% )	/	( (9766.167	+	10371.615)	/ 2 )
=	311.2290684	/	10068.891
=	3.09 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11895.943	-	370.783	-	( 1758.993	-	max(0, 558.176	-	3146.77	+	1758.993	))
=	9766.167

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12299.07	-	320.313	-	( 1607.142	-	max(0, 522.799	-	3048.33	+	1607.142	))
=	10371.615

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Bio-Rad Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1763.012	/	( ( (711.402 + max(869.193, 0))	+	(723.73 + max(959.254, 0)) )	/	2 )
=	1763.012	/	( ( 1580.595	+	1682.984 )	/	2 )
=	1763.012	/	1631.7895
=	108.04 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(457.402	+	775.818	+	154.557)	-	(370.783	+	0	+	147.801)
=	869.193

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(489.017	+	780.517	+	171.654)	-	(320.313	+	0	+	161.621)
=	959.254

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bio-Rad Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-800.665	/	7786.049
	=	-10.28 %

Bio-Rad Laboratories EBIT Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

BIO.B:USA BUW:Germany BUWA:Germany

Address

1000 Alfred Nobel Drive, Hercules, CA, USA, 94547

Website

https://www.bio-rad.com

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Executives

Tania Devilliers	officer: INT PRIN ACCTG OFC	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Sedat Evran	officer: EVP, Global Supply Chain	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Corey Colleen	officer: EVP, Global Human Resources	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Diane Dahowski	officer: EVP, Global Supply Chain	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Schwartz Allison	director	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Simon May	officer: EVP, President, LSG	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew J. Last	officer: EVP, Chief Operating Officer	3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Ajit Ramalingam	officer: SVP, Chief Accounting Officer	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Ilan Daskal	officer: EVP, Chief Financial Officer	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Timothy S Ernst	officer: EVP, General Counsel & Sec	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Dara Wright	officer: Executive Vice President	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Michael Crowley	officer: EVP, GBL Commercial Operations	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Steven D Schwartz	10 percent owner	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Alice N Schwartz	director, 10 percent owner
Norman D Schwartz	director, 10 percent owner, officer: Chairman, President, and CEO	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547